• Aliases: Erismodegib, LDE225
    • An orally bioavailable small-molecule smoothened (SMO) antagonist that selectively binds to the hedgehog (Hh)-ligand cell surface receptor SMO, which may result in the suppression of the Hh signaling pathway
    • FDA approved for locally advanced basal cell carcinoma
    • Recommended dose: 200 mg daily
    • Half-life: â™28 days (<10% is orally absorbed)
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Fatigue, alopecia, hyperglycemia, weight loss, transaminitis, increase amylase/lipase, anemia, increased CPK, muscle spasms, increased SCr, myalgias
    Other topics in Targeted and Immunotherapy Agents